Avelas Biosciences Grows Management Team

March 4, 2019

SAN DIEGO, March 4, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, today announced the addition of William Stratton as Head of Business Development. Mr. Stratton joins Avelas to lead business development, partnering, and corporate strategy functions.

 

“We are excited to bring Will on to the Avelas management team as we enter a new phase for the company, where his skillset will be of great value to our business development and partnering activities,” said Jay Lichter, Chief Executive Officer of Avelas. “We are on a mission to improve the lives of cancer patients by providing real-time cancer detection with AVB-620. Will is going to be an important part of helping us mature as an organization and execute on our strategy.”

 

Mr. Stratton has worked extensively in oncology business development, recently holding positions in business development and corporate strategy at Rakuten Medical and NAVICAN Genomics. Mr. Stratton started his career working in consulting, advising clients in the life sciences and healthcare technology sectors while at The Amundsen Group (a division of IQVIA) and The Exeter Group. Mr. Stratton holds a B.S. in chemistry from Yale University and an MBA with concentrations in Healthcare Management and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.

 

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 improves surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.

« Return